Table 2.
The expression levels of miRNAs
| miRNA | Samples | Mean ± SD (PC vs control) | Fold change (PC/control) | P value | Refs |
|---|---|---|---|---|---|
| miR‐7 | 20 pairs of tumors and adjacent normal tissues | 1.7 ± 1.04 vs 1.21 ± 0.55 | 0.6569 | 33 | |
| miR‐7‐2* | 44 pairs of PC and normal | 0.806642 | 2.19E‐02 | 114 | |
| miR‐7c | 50 PC and 10 normal | 0.001272 | 1.56E‐02 | 21 | |
| miR‐9 | 51 localized PC | 0.96 ± 0.89 vs 1.34 ± 2.47 | 0.637 | 15 | |
| miR‐9‐1 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 5.9 vs 4.98 | 0.04723 | 115 | |
| miR‐9‐2 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 5.89 vs 4.97 | 0.04892 | 115 | |
| miR‐9‐3 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 6.12 vs 4.96 | 0.01907 | 115 | |
| miR‐15b | 40 PC and 10 normal | 3.4761 | 0.0418 | 23 | |
| miR‐18b | 40 PC and 10 normal | 6.8061 | 0.0133 | 23 | |
| miR‐20b | 40 PC and 10 normal | 3.1928 | 0.0501 | 23 | |
| miR‐22 | 4 frozen tissue samples 1 FFPE prostate sample | 3.2 | NM | 113 | |
| miR‐24 | 50 PC and 10 normal | 0.27 | 3.68E‐03 | 21 | |
| miR‐24‐2 | 50 PC and 10 normal | 0.164459 | 9.76E‐03 | 21 | |
| miR‐26a‐5p | 140 pairs of fresh PC tissues and normal tissues | 0.058 ± 0.016 vs 0.115 ± 0.043 | <0.001 | 45 | |
| miR‐28‐3p | 50 PC and 10 normal | 0.00668 | 1.08E‐02 | 21 | |
| miR‐28‐5p | 50 PC and 10 normal | 0.003839 | 3.28E‐03 | 21 | |
| miR‐29b | 51 localized PC | 0.51 ± 0.64 vs 0.56 ± 0.77 | 0.852 | 15 | |
| miR‐30a | 51 localized PC | 6.37 ± 7.91 vs 1.7 ± 2.77 | 0.039 | 15 | |
| miR‐30c‐1 | 50 PC and 10 normal | 0.257951 | 3.18E‐02 | 21 | |
| miR‐30d | 56 pairs of primary PC and control | 7.95 ± 7.03 vs 6.23 ± 6.06 | 0.03 | 48 | |
| miR‐30e* | 44 pairs of PC and normal | 0.840896 | 4.10E‐03 | 114 | |
| miR‐33a | Paired prostate cancer tissue and adjacent normal tissue | 0.1389 | <0.01 | 50 | |
| miR‐34c‐3p | 50 PC and 10 normal | 0.17691 | 7.42E‐03 | 21 | |
| miR‐34c‐5p | 40 PC and 10 normal | 8.0395 | 0.0283 | 23 | |
| miR‐92a | 40 PC and 10 normal | 3.0015 | 0.0177 | 23 | |
| miR‐93 | 197 PC and 43 normal | 2.14 | 1.69E‐09 | 116 | |
| miR‐96 | 197 PC and 43 normal | 2.35 | 2.33E‐12 | 116 | |
| miR‐101 | 8 PC and 12 BPH | 0.91 | >0.05 | 18 | |
| miR‐122 | 40 PC and 10 normal | 5.5663 | 0.0054 | 23 | |
| miR‐126 | 128 PCa | 1.05 ± 0.63 vs 2.92 ± 0.98 | <0.001 | 55 | |
| miR‐126‐5p | 12 G > 7, 12 G7, and 12 non‐cancerous samples | 2.22 | <0.05 | 97 | |
| miR‐128 | 128 PC tissue and serum and matched normal | 1.05 ± 0.63 vs 2.92 ± 0.98 | <0.001 | 56 | |
| miR‐128a | 40 PC and 10 normal | 4.5004 | 0.0143 | 23 | |
| miR‐130b | 197 PC and 43 normal | 1.974463 | 3.52E‐07 | 116 | |
| miR‐134 | 40 PC and 10 normal | 23.1323 | 0.0125 | 23 | |
| miR‐135b | 40 PC and 10 normal | 4.0019 | 0.0141 | 23 | |
| miR‐138‐2 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 5.23 vs 4.25 | 0.03941 | 115 | |
| miR‐139 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 7.24 vs 8.08 | 0.03061 | 115 | |
| miR‐146b‐5p | 40 PC and 10 normal | 3.5577 | 0.0019 | 23 | |
| miR‐148b | 40 PC and 10 normal | 2.8135 | 0.0358 | 23 | |
| miR‐149 | 44 pairs of PC and normal | 0.796 | 0.416 | 114 | |
| miR‐151a‐5p | 12 G > 7, 12 G7, and 12 non‐cancerous samples | 2.02 | <0.05 | 97 | |
| miR‐153 | 197 PC and 43 normal | 3.1425 | 2.74E‐13 | 116 | |
| miR‐155 | 51 localized PC | 3.12 ± 4.56 vs 2.09 ± 3.8 | 0.463 | 15 | |
| miR‐181d | 50 PC and 10 normal | 0.062341 | 9.34E‐03 | 21 | |
| miR‐182‐5p | patient set 1:69 PC patient set 2:10 PC | Patient set 1: 1.745 ± 0.278 vs 0.864 ± 0.136 Patient set 2: 1.863 ± 0.381 vs 0.761 ± 0.158 | 0.021 | 66 | |
| miR‐183* | 44 pairs of PC and normal | 1.505247 | 7.68E‐03 | 114 | |
| miR‐184 | 40 PC and 10 normal | 4.0633 | 0.0086 | 23 | |
| miR‐188 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 8.48 vs 7.5 | 0.01878 | 115 | |
| miR‐188‐5p | 180 pairs of PC and normal | 0.0956 | NM | 68 | |
| miR‐193a‐5p | 40 PC and 10 normal | 4.5984 | 0.0094 | 23 | |
| miR‐193b | 40 PC and 10 normal | 12.649 | 0.0021 | 23 | |
| miR‐199a‐1 | 50 PC and 10 normal | 0.451942 | 2.06E‐02 | 21 | |
| miR‐199a‐3p | 50 PC and 10 normal | 0.000759 | 1.08E‐02 | 21 | |
| miR‐214 | 40 PC and 10 normal | 9.9075 | 0.0055 | 23 | |
| miR‐215 | 40 PC and 10 normal | 8.4863 | 0.038 | 23 | |
| miR‐220a | 44 pairs of PC and normal | 0.907519 | 0.355 | 114 | |
| miR‐221‐3p | 12 G > 7, 12 G7, and 12 non‐cancerous samples | 5.47 | <0.05 | 97 | |
| miR‐222‐3p | 12 G > 7, 12 G7, and 12 non‐cancerous samples | 3.88 | <0.05 | 97 | |
| miR‐223 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 10.66 vs 11.9 | 0.00179 | 115 | |
| miR‐223‐3p | 10 pairs of PC and adjacent non‐cancerous tissues | 2.98 ± 1.45 vs 1.55 ± 0.38 | <0.01 | 75 | |
| miR‐296 | TMA100: 100 PC cases TMA96: 96 cases | 1.79 ± 0.19 vs 2.71 ± 0.16 | <0.05 | 79 | |
| miR‐296‐5p | 44 pairs of PC and normal | 0.646176 | 1.49E‐02 | 114 | |
| miR‐301b | 18 PC with recurrence and 13 PC no metastasis no recurrence | 4.61 vs 3.65 | 0.02116 | 115 | |
| miR‐320c‐2 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 3.54 vs 2.39 | 0.0393 | 115 | |
| miR‐324‐5p | 197 PC and 43 normal | 0.565156 | 2.06E‐05 | 116 | |
| miR‐328 | 197 PC and 43 normal | 0.511 | 7.85E‐07 | 116 | |
| miR‐335 | 20 pairs of primary PC and adjacent 104 PC and 20 benign | 3.27 ± 0.99 vs. 4.55 ± 1.34 | <0.05 | 82 | |
| miR‐338‐5p | 50 PC and 10 normal | 14.70974 | 9.88E‐03 | 21 | |
| miR‐362‐3p | 50 PC and 10 normal | 0.265027 | 3.18E‐02 | 21 | |
| miR‐372 | 40 PC and 10 normal | 6.8639 | 0.0184 | 23 | |
| miR‐373 | 51 localized PC | 0.26 ± 0.37 vs. 0.29 ± 0.32 | 0.186 | 15 | |
| miR‐376a | 50 PC and 10 normal | 0.457502 | 1.41E‐02 | 21 | |
| miR‐378* | 197 PC and 43 normal | 0.476022 | 1.64E‐08 | 116 | |
| miR‐378c | 50 PC and 10 normal | 0.011878 | 1.40E‐03 | 21 | |
| miR‐381 | 50 PC and 10 normal | 0.20897 | 2.30E‐02 | 21 | |
| miR‐383 | TCGA:187 primary PC validation cohort: 112 pairs of PC and adjacent normals | 0.25 | 0.05 | 84 | |
| miR‐411 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 3.83 vs 2.73 | 0.02673 | 115 | |
| miR‐421 | 50 PC and 10 normal | 0.03487 | 6.02E‐04 | 21 | |
| miR‐422a | 50 PC and 10 normal | 0.014149 | 8.65E‐05 | 21 | |
| miR‐424 | 50 PC and 10 normal | 0.088399 | 2.94E‐02 | 21 | |
| miR‐429 | 51 localized PC | 7.74 ± 7.34 vs 7.75 ± 17.18 | 0.998 | 15 | |
| miR‐433 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 4.21 vs 3.15 | 0.030601 | 115 | |
| miR‐455‐3p | 50 PC and 10 normal | 0.001986 | 2.07E‐02 | 21 | |
| miR‐455‐5p | 50 PC and 10 normal | 0.093956 | 9.76E‐03 | 21 | |
| miR‐485‐3p | 50 PC and 10 normal | 0.2564 | 1.82E‐02 | 21 | |
| miR‐486 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 4.49 vs 5.6 | 0.03746 | 115 | |
| miR‐486‐5p | 12 G > 7, 12 G7, and 12 non‐cancerous samples | 0.3937 | <0.05 | 97 | |
| miR‐487b | 197 PC and 43 normal | 0.565379 | 3.69E‐05 | 116 | |
| miR‐489 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 3.66 vs 2.67 | 0.02183 | 115 | |
| miR‐490‐5p | 50 PC and 10 normal | 0.184615 | 1.56E‐02 | 21 | |
| miR‐495 | 51 localized PC | 0.77 ± 0.39 vs 0.93 ± 0.32 | 0.78 | 15 | |
| miR‐497 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 11.19 vs 10.28 | 0.01111 | 115 | |
| miR‐501 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 5.74 vs 4.91 | 0.00525 | 115 | |
| miR‐502‐5p | 197 PC and 43 normal | 0.573804 | 3.86E‐05 | 116 | |
| miR‐503 | 50 PC and 10 normal | 0.376508 | 1.41E‐02 | 21 | |
| miR‐507 | PC and matched Normal | 0.858565 | 4.88E‐03 | 114 | |
| miR‐509‐3‐5p | 50 PC and 10 normal | 0.318223 | 3.62E‐02 | 21 | |
| miR‐509‐5p | 20 PC, 20 tumor‐adjacent tissues, and 20 normal prostate tissues | 0.314 ± 0.048 vs 1.532 ± 0.015 | <0.05 | 87 | |
| miR‐518b | 44 pairs of PC and normal | 0.779165 | 4.23E‐02 | 114 | |
| miR‐543 | 50 PC and 10 normal | 0.270522 | 1.08E‐02 | 21 | |
| miR‐545 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 5.1 vs 4.04 | 0.00524 | 115 | |
| miR‐574‐3p | 48 pairs of PC and adjacent non‐cancerous tissues | 0.5 | <0.0001 | 89 | |
| miR‐612 | 44 pairs of PC and normal | 1.658639 | 5.31E‐03 | 114 | |
| miR‐624 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 5.66 vs 4.07 | 0.030601 | 115 | |
| miR‐628‐3p | 50 PC and 10 normal | 0.04014 | 1.80E‐03 | 21 | |
| miR‐650 | 216 PC, 324 benign, and 77 control 22 PC, 20 benign, and 11 control | 1.29 ± 0.08 vs 1.07 ± 0.05 | 0.012 | 90 | |
| miR‐652 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 8.3 vs 6.73 | 0.00124 | 115 | |
| miR‐659 | 44 pairs of PC and normal | 0.795536 | 4.10E‐03 | 114 | |
| miR‐663 | 197 PC and 43 normal | 0.545382 | 2.62E‐09 | 116 | |
| miR‐671 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 7.75 vs 6.94 | 0.00072 | 115 | |
| miR‐708 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 6.67 vs 5.45 | 0.01206 | 115 | |
| miR‐875‐3p | 50 PC and 10 normal | 0.383402 | 3.12E‐02 | 21 | |
| miR‐875‐5p | 44 pairs of PC and normal | 0.632878 | 1.31E‐02 | 114 | |
| miR‐887 | 50 PC and 10 normal | 0.211747 | 2.33E‐02 | 21 | |
| miR‐1184 | 50 PC and 10 normal | 3.450542 | 1.56E‐02 | 21 | |
| miR‐1206 | 44 pairs of PC and normal | 0.907519 | 2.68E‐02 | 114 | |
| miR‐1207‐3p | PC patients of 389 CA and 15 AA | Black: 3.00 ± 2.65 White 5.36 ± 3.76 | 0.062 | 93 | |
| miR‐1207‐5p | 50 PC and 10 normal | 180.2841 | 4.72E‐02 | 21 | |
| miR‐1228 | 44 pairs of PC and normal | 1.086735 | 4.90E‐02 | 114 | |
| miR‐1238 | 50 PC and 10 normal | 0.883057 | 2.36E‐02 | 21 | |
| miR‐1244 | 44 pairs of PC and normal | 1.484524 | 5.20E‐03 | 114 | |
| miR‐1245 | 44 pairs of PC and normal | 1.265757 | 3.01E‐02 | 114 | |
| miR‐1248 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 8.91 vs 7.77 | 0.01907 | 115 | |
| miR‐1249 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 5.37 vs 4.47 | 0.00622 | 115 | |
| miR‐1271 | 50 PC and 10 normal | 0.02573 | 3.28E‐03 | 21 | |
| miR‐1302‐1 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 4.53 vs 2.75 | 0.01529 | 115 | |
| miR‐1302‐3 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 4.42 vs 2.75 | 0.01529 | 115 | |
| miR‐1302‐7 | 18 PC with recurrence and 13 PC no metastasis no recurrence | 4.19 vs 2.55 | 0.02113 | 115 | |
| miR‐3200‐3p | 50 PC and 10 normal | 0.40029 | 4.48E‐02 | 21 | |
| miR‐4288 | 50 PC and 10 normal | 0.219167 | 3.76E‐03 | 21 | |
| miR‐4328 | 50 PC and 10 normal | 0.470068 | 4.96E‐02 | 21 | |
| miR‐4638‐5p | 3 CRPC and 3 ADPC 18 CRPC and 30 ADPC | 0.4167 0.2128 | 1.44E‐08 | 95 | |
| let‐7b | Cohort A: 6 BPH tissues and 13 high‐risk PC specimens Cohort B: 92 FFPE PC samples Cohort C: 21 pairs of fresh frozen PC tissue and adjacent benign tissue | 3.16 ± 0.76 vs 3.8 ± 0.37 | <0.01 | 107 |
Refs, reference; PC, prostate cancer; BPH, benign prostate hyperplasia; CRPC, castration resistant prostate cancer.